Biomarin Pharmaceutical (BMRN) Amortization - Intangibles (2009 - 2026)

Biomarin Pharmaceutical has disclosed Amortization - Intangibles across 18 years of filings, most recently posting $4.5 million for Q1 2026.

• Quarterly Amortization - Intangibles fell 7.51% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.0 million (down 43.73% YoY) and the FY2025 annual result came in at $19.4 million, down 55.18% from the prior year.
• Amortization - Intangibles declined to $4.5 million in Q1 2026, from $4.8 million in the prior quarter.
• Over five years, Amortization - Intangibles peaked at $17.6 million in Q1 2022 and troughed at $4.5 million in Q1 2026.
• A 5-year average of $11.6 million and a median of $14.3 million in 2024 frame the typical range for Amortization - Intangibles.
• Annual changes were most pronounced in 2022 — Amortization - Intangibles slipped 0.69% — and 2024, when it tumbled 68.06%.
• Tracing BMRN's Amortization - Intangibles over 5 years: stood at $16.3 million in 2022, then decreased by 6.29% to $15.2 million in 2023, then sank by 36.66% to $9.7 million in 2024, then tumbled by 49.79% to $4.8 million in 2025, then dropped by 7.49% to $4.5 million in 2026.
• Business Quant data shows BMRN's Amortization - Intangibles at $4.5 million in Q1 2026, $4.8 million in Q4 2025, and $4.8 million in Q3 2025.